高级检索
当前位置: 首页 > 详情页

The Inactivation of Hippo Signaling Pathway Promotes the Development of Adenomyosis by Regulating EMT, Proliferation, and Apoptosis of Cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China [2]Engineering Technology Research Center of Drug Development for Small Nucleic Acids, Guangzhou 510632, Guangdong, China [3]Department of Gynecology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, Guangdong, China
出处:
ISSN:

关键词: Adenomyosis (ADM)  YAP (Yes-associated protein)  Hippo signaling pathway  Epithelial-mesenchymal transition (EMT)

摘要:
Adenomyosis is a benign gynecological disease. The pathogenesis of adenomyosis is still unclear. The Hippo signaling pathway is highly conserved in vivo and associated with endometriosis and various cancers. Our objective was to study the expression of Hippo signaling pathway-related proteins in the uterus of mice with and without adenomyosis. We also sought to determine the relationship between the Hippo signaling pathway and cell migration, invasion, proliferation, and apoptosis in adenomyosis. The inactivation of Hippo signaling pathway and abnormal expression of EMT-related proteins were observed in mice with adenomyosis. In vitro, the YAP inhibitor verteporfin can inhibit the proliferation and migration of Ishikawa cells and promote apoptosis, while inhibiting the EMT process. In addition, intraperitoneal injection of verteporfin inhibits EMT process and proliferation and promotes apoptosis of cells in the uterus of adenomyosis mice. It suggests that the Hippo signaling pathway participates in the EMT, proliferation, and apoptosis of cells in adenomyosis. In conclusion, these results suggest that Hippo signaling pathway may be involved in the development of adenomyosis by regulating EMT, proliferation, and apoptosis of cells, which provide a potential target for the treatment of adenomyosis.© 2023. The Author(s).

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 妇产科学 4 区 生殖生物学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 妇产科学 4 区 生殖生物学
JCR分区:
出版当年[2021]版:
Q3 OBSTETRICS & GYNECOLOGY Q3 REPRODUCTIVE BIOLOGY
最新[2023]版:
Q2 OBSTETRICS & GYNECOLOGY Q2 REPRODUCTIVE BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China [2]Engineering Technology Research Center of Drug Development for Small Nucleic Acids, Guangzhou 510632, Guangdong, China
通讯作者:
通讯机构: [1]Department of Biochemistry and Molecular Biology, School of Medicine, Jinan University, Guangzhou 510632, Guangdong, China [2]Engineering Technology Research Center of Drug Development for Small Nucleic Acids, Guangzhou 510632, Guangdong, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2022 今日访问量:0 总访问量:648 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号